Background: The Fracture Intervention Trial (FIT) demonstrated that the bisphosphonate alendronate reduces the risk of hip, spine and wrist fracture in osteoporotic women by approximately one half. Objective: To use data from FIT to conduct a cost-effectiveness analysis of alendronate. Design: A...

The most well established antithrombotic treatment for acute coronary syndromes (ACS) is unfractionated heparin (UFH) plus aspirin, but such treatment may not prevent arterial thrombotic events. Low molecular weight heparins (LMWHs) and platelet glycoprotein (GP) IIb/IIIa inhibitors offer...

Objective: To investigate the relationship between cognitive impairment, measured with the Mini Mental State Examination (MMSE), and the cost of care. Design: The study uses data from the Kungsholmen project, a population-based study in Sweden in which people 75 years and older were observed...

Background: The Multiple Outcomes of Raloxifene Evaluation (MORE) study showed that treatment with raloxifene reduces the risk of vertebral fracture and breast cancer in postmenopausal women with osteoporosis. Objective: Based on the MORE study the aim of the present study was to assess the cost...

Objective: To investigate the cost effectiveness of adding the beta-blocker bisoprolol to standard treatment in patients with congestive heart failure (CHF). Design and setting: A cost-effectiveness study was based on the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), a randomised...

No consensus has yet been reached on how to analyse uncertainty in economic evaluation studies where individual patient data are available for costs and health effects. This paper summarises the available results regarding the analysis of uncertainty on the cost-effectiveness plane and argues...